Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ARMSTRONG J. B., WHITE J. C. Liquefaction of viscous purulent exudates by deoxyribonuclease. Lancet. 1950 Dec 9;2(6641):739–742. doi: 10.1016/s0140-6736(50)91676-x. [DOI] [PubMed] [Google Scholar]
- Aitken M. L., Burke W., McDonald G., Shak S., Montgomery A. B., Smith A. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA. 1992 Apr 8;267(14):1947–1951. [PubMed] [Google Scholar]
- CHERNICK W. S., BARBERO G. J. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics. 1959 Nov;24:739–745. [PubMed] [Google Scholar]
- CHERNICK W. S., BARBERO G. J., EICHEL H. J. In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients withcystic fibrosis. Pediatrics. 1961 Apr;27:589–596. [PubMed] [Google Scholar]
- Cooper P. J., Robertson C. F., Hudson I. L., Phelan P. D. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol. 1990;8(1):16–22. doi: 10.1002/ppul.1950080107. [DOI] [PubMed] [Google Scholar]
- Fuchs H. J., Borowitz D. S., Christiansen D. H., Morris E. M., Nash M. L., Ramsey B. W., Rosenstein B. J., Smith A. L., Wohl M. E. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994 Sep 8;331(10):637–642. doi: 10.1056/NEJM199409083311003. [DOI] [PubMed] [Google Scholar]
- Hubbard R. C., McElvaney N. G., Birrer P., Shak S., Robinson W. W., Jolley C., Wu M., Chernick M. S., Crystal R. G. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med. 1992 Mar 19;326(12):812–815. doi: 10.1056/NEJM199203193261207. [DOI] [PubMed] [Google Scholar]
- Lieberman J. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis. JAMA. 1968 Jul 29;205(5):312–313. [PubMed] [Google Scholar]
- Nickerson B. G., Lemen R. J., Gerdes C. B., Wegmann M. J., Robertson G. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis. 1980 Dec;122(6):859–866. doi: 10.1164/arrd.1980.122.6.859. [DOI] [PubMed] [Google Scholar]
- Ranasinha C., Assoufi B., Shak S., Christiansen D., Fuchs H., Empey D., Geddes D., Hodson M. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993 Jul 24;342(8865):199–202. doi: 10.1016/0140-6736(93)92297-7. [DOI] [PubMed] [Google Scholar]
- Raskin P. Bronchospasm after inhalation of pancreatic dornase. Am Rev Respir Dis. 1968 Oct;98(4):697–698. doi: 10.1164/arrd.1968.98.4.697. [DOI] [PubMed] [Google Scholar]
- Robson M., Abbott J., Webb K., Dodd M., Walsworth-Bell J. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients. Thorax. 1992 Sep;47(9):684–689. doi: 10.1136/thx.47.9.684. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shak S., Capon D. J., Hellmiss R., Marsters S. A., Baker C. L. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990 Dec;87(23):9188–9192. doi: 10.1073/pnas.87.23.9188. [DOI] [PMC free article] [PubMed] [Google Scholar]